上海赛伦生物技术股份有限公司（以下简称"公司）于 2023 年 7 月 31 日披 露了《上海赛伦生物技术股份有限公司关于公司实际控制人之一、董事长被留置 并立案调查的公告》（公告编号：2023-019），公司实际控制人之一、董事长、 法定代表人范志和先生被上海市监察委员会实施留置并立案调查。 2023 年 10 月 29 日，公司收到范志和先生家属通知，其收到上海市监察委 员会签发的《解除留置通知书》，范志和先生已于当日解除留置措施。 目前范志和先生已能正常履行公司董事长、法定代表人等职责，公司董事、 总经理范铁炯先生不再代为履行公司董事长、法定代表人以及公司董事会相关委 员会成员的职责。 关于公司实际控制人之一、董事长解除留置的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 公司指定的信息披露媒体为《上海证券报》、《中国证券报》、《证券时报》、 《证券日报》及上海证券交易所网站（www.sse.com.cn），公司发布的信息均以 在上述指定媒体刊登的信息为准。敬请广大投资者理性投资，注意投资风险。 特此公告。 证 ...

Financial Performance - The company's operating revenue for Q3 2023 was ¥72,374,219.80, representing a year-on-year increase of 1.61%[5] - The net profit attributable to shareholders for Q3 2023 was ¥23,888,496.42, a decrease of 26.06% compared to the same period last year[5] - The net profit after deducting non-recurring gains and losses for Q3 2023 was ¥20,060,071.43, down 25.97% year-on-year[6] - The net profit for Q3 2023 was CNY 50,797,820.53, a decrease of 19.1% compared to CNY 62,771,140.81 in Q3 2022[21] - Total revenue for the first three quarters of 2023 reached ¥166,133,808.11, an increase of 11.3% compared to ¥149,434,599.86 in the same period of 2022[30] - Net profit for the first three quarters of 2023 was ¥52,373,135.70, a decrease of 17.0% compared to ¥63,106,277.36 in the same period of 2022[31] Research and Development - The total R&D investment for Q3 2023 was ¥13,108,615.11, an increase of 249.91% compared to the same period last year[6] - R&D investment accounted for 18.11% of operating revenue in Q3 2023, up 12.85 percentage points year-on-year[6] - The company is focusing on the development of new products, including antivenom serums and rapid diagnostic reagents, which have seen increased R&D investment[10] - Research and development expenses increased significantly to CNY 22,111,264.41, up from CNY 9,537,393.92, representing a growth of 132.5% year-over-year[20] - Research and development expenses increased significantly to ¥22,459,586.29, up 132.5% from ¥9,675,989.56 in the first three quarters of 2022[30] Cash Flow and Liquidity - The net cash flow from operating activities for the year-to-date period decreased by 70.16% to ¥18,739,814.65[9] - The cash flow from operating activities for the first nine months of 2023 was CNY 18,739,814.65, a decrease from CNY 62,795,469.40 in the same period last year[24] - The company reported a net cash outflow from investing activities of CNY -331,567,873.09 for Q3 2023, compared to CNY -753,906,332.87 in Q3 2022[24] - Cash and cash equivalents decreased to RMB 121,998,400.36 from RMB 515,730,469.86 at the end of 2022, showing a decline of approximately 76.4%[15] - The ending cash and cash equivalents balance was ¥121,896,594.12, up from ¥110,970,437.54, reflecting an increase of 9.0%[34] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,129,138,906.13, a decrease of 2.92% from the end of the previous year[6] - As of September 30, 2023, total current assets amounted to RMB 956,456,829.05, a decrease from RMB 997,054,745.62 at the end of 2022, reflecting a decline of about 4.9%[15] - The company's total assets as of September 30, 2023, were RMB 1,129,138,906.13, down from RMB 1,163,066,774.97 at the end of 2022, a decrease of about 2.9%[17] - Non-current liabilities totaled RMB 17,672,174.07 as of September 30, 2023, compared to RMB 14,904,469.77 at the end of 2022, indicating an increase of approximately 18.5%[17] - The company's total liabilities decreased to RMB 37,874,811.76 from RMB 41,776,323.39 at the end of 2022, reflecting a reduction of about 9.4%[17] Earnings and Shareholder Equity - The weighted average return on equity for Q3 2023 was 2.21%, a decrease of 0.72 percentage points year-on-year[6] - The basic earnings per share for Q3 2023 was ¥0.22, down 29.03% compared to the same period last year[6] - Basic and diluted earnings per share for Q3 2023 were both CNY 0.47, down from CNY 0.63 in Q3 2022[21] - The company's retained earnings as of September 30, 2023, were RMB 69,947,592.08, down from RMB 99,973,949.29 at the end of 2022, indicating a decline of approximately 30.1%[17] - The total equity attributable to shareholders decreased to RMB 1,091,264,094.37 from RMB 1,121,290,451.58 at the end of 2022, a decrease of about 2.7%[17]

证券代码：688163 证券简称：赛伦生物 公告编号：2023-025 上海赛伦生物技术股份有限公司 关于独立董事任期届满暨延期选举独立董事的公告 本公司董事会及除董事长范志和先生外的全体董事保证本公告内容不存在 任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整 性依法承担法律责任。 上海赛伦生物技术股份有限公司（以下简称"公司"）独立董事庄建伟先生、 章建康先生于 2017 年 9 月 22 日起任公司独立董事，任期于 2023 年 9 月 21 日 届满六年。根据《上市公司独立董事管理办法》及相关规定，独立董事连续任职 不得超过六年，公司应召开股东大会补选独立董事。鉴于本次拟补选独立董事的 候选人提名工作仍在推进，为确保公司董事会工作的连续性及稳定性，本次选举 独立董事将适当延期。 独立董事庄建伟先生、章建康先生期满离任将导致公司独立董事人数及比例 低于《上市公司独立董事管理办法》及《公司章程》规定的最低人数及比例，庄 建伟先生、章建康先生离任将在公司股东大会选举产生新任独立董事填补缺额后 生效。在此期间，庄建伟先生、章建康先生将按照法律法规及《公司章程》的有 关规定，继续履行独立董 ...

方正证券承销保荐有限责任公司 关于上海赛伦生物技术股份有限公司 2023 年半年度持续督导跟踪报告 根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板股票上市 规则（2023 年 8 月修订）》《上海证券交易所上市公司自律监管指引第 11 号— 持续督导》《科创板上市公司持续监管办法（试行）》等有关法律、法规的规定， 方正证券承销保荐有限责任公司（以下简称"保荐机构"）作为上海赛伦生物技 术股份有限公司（以下简称"赛伦生物"、"公司"）首次公开发行股票并在科 创板上市的保荐机构，负责赛伦生物上市后的持续督导工作。 注：2023 年 7 月 29 日，公司收到实际控制人之一、董事长、法定代表人范志和家属的 通知，范志和家属于 2023 年 7 月 29 日收到上海市监察委员会签发的《留置通知书》和《立 案通知书》，范志和先生因涉嫌职务犯罪被实施留置并立案调查。具体情况详见公司 2023 年 7 月 31 日于上海证券交易所网站（www.sse.com.cn）披露的《关于公司实际控制人之一、 董事长被留置并立案调查的公告》。 2023 年 8 月 1 日公司收到上海证券交易所下发的《关于上海赛伦生物技术股 ...

证券代码：688163 证券简称：赛伦生物 公告编号：2023-024 上海赛伦生物技术股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及除董事长范志和外的全体董事保证本公告内容不存在任何 虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 重要内容提示： 会议召开时间：2023 年 9 月 18 日（星期一）下午 14:00-15:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 9 月 11 日（星期一）至 9 月 15 日（星期五）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 dmb@serum-china.com 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 上海赛伦生物技术股份有限公司（以下简称"公司"）已于 2023 年 8 月 29 日发布公司 2023 年半年度报告，为便于广大投资者更全面深入地了解公司 2023 年 ...

关于首次公开发行部分限售股上市流通的公告 本公司董事会及除董事长范志和先生外的全体董事保证本公告内容不存在 任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整 性依法承担法律责任。 重要内容提示： 一、本次上市流通的限售股类型 根据中国证券监督管理委员会于 2022 年 1 月 25 日出具的《关于同意上海赛 伦生物技术股份有限公司首次公开发行股票注册的批复》（证监许可【2022】204 号），同意公司首次公开发行股票的注册申请。公司首次向社会公众公开发行人 民币普通股（A 股）股票 27,060,000 股，并于 2022 年 3 月 11 日在上海证券交易 所科创板上市，发行完成后股本总数为 108,220,000 股，其中有限售条件流通股 83,456,396 股，占公司股本总数的 77.12%，无限售条件流通股 24,763,604 股，占 公司股本总数的 22.88%。 本次上市流通的限售股为公司首次公开发行部分限售股，原始限售期为自公 司首次公开发行股票上市之日起 12 个月。因触发延长锁定期相关承诺，公司股 东何毅明、成琼、张浩、张志平持有的公司股份在原锁定期的基础上自动延长 ...

方正证券承销保荐有限责任公司 关于上海赛伦生物技术股份有限公司 首次公开发行部分限售股上市流通的核查意见 方正证券承销保荐有限责任公司（以下简称"保荐机构"）作为上海赛伦生 物技术股份有限公司（以下简称"公司"或"赛伦生物"）首次公开发行股票并 在科创板上市及持续督导的保荐机构，根据《上海证券交易所科创板股票上市规 则（2020 年 12 月修订）》《上海证券交易所科创板上市公司自律监管指引第 1 号 —规范运作》以及《科创板上市公司持续监管办法（试行）》等相关规定，对赛 伦生物首次公开发行部分限售股上市流通事项进行了核查，情况如下： 一、本次上市流通的限售股类型 根据中国证券监督管理委员会于 2022 年 1 月 25 日出具的《关于同意上海赛 伦生物技术股份有限公司首次公开发行股票注册的批复》（证监许可[2022]204 号），同意公司首次公开发行股票的注册申请。公司首次向社会公众公开发行人 民币普通股（A 股）股票 27,060,000 股，并于 2022 年 3 月 11 日在上海证券交易 所科创板上市，发行完成后股本总数为 108,220,000 股，其中有限售条件流通股 83,456,396 股， ...

Financial Performance - The company reported a total revenue of 500 million CNY for the first half of 2023, representing a 20% increase compared to the same period last year[14]. - The company's operating revenue for the first half of 2023 was ¥93,759,588.31, an increase of 19.88% compared to ¥78,210,546.60 in the same period last year[20]. - The net profit attributable to shareholders decreased by 11.67% to ¥26,909,324.11 from ¥30,463,090.64 year-on-year[22]. - The net cash flow from operating activities dropped significantly by 188.62%, resulting in a negative cash flow of ¥18,887,952.07[22]. - The company's total assets decreased by 4.87% to ¥1,106,471,391.92 from ¥1,163,066,774.97 at the end of the previous year[20]. - The basic earnings per share fell by 21.88% to ¥0.25 from ¥0.32 in the same period last year[21]. - The company's net assets attributable to shareholders decreased by 4.81% to ¥1,067,375,597.95 from ¥1,121,290,451.58 at the end of the previous year[20]. - The company reported a decrease in gross profit margin due to rising product sales costs and increased selling and R&D expenses[22]. - The company achieved a net profit attributable to shareholders of 26.91 million yuan in the first half of 2023, a decrease of 11.67% compared to the same period last year, primarily due to a decline in sales of tetanus immunoglobulin and increased production costs[64]. Research and Development - Research and development expenses accounted for 9.60% of operating revenue, an increase of 2.20 percentage points compared to 7.40% in the previous year[21]. - The company has achieved a 55.46% increase in research and development (R&D) expenses, totaling ¥9,002,649.30 compared to ¥5,791,126.70 in the same period last year[50]. - R&D expenses for the period amounted to CNY 9.00 million, representing a year-on-year increase of 55.46% due to increased investment in new projects[63]. - The company is developing a rapid diagnostic reagent for snake venom with a total investment of CNY 13.50 million, currently in the preclinical research stage[53]. - The company has ongoing R&D projects with a total investment of CNY 230.85 million, of which CNY 8.86 million was invested in the current period, and cumulative investment reached CNY 78.95 million[53]. - The company has developed various immune adjuvants to enhance the immune response, crucial for producing high-efficacy antiserum[43]. - The company has focused on toxin proteomics research to analyze pathogenic mechanisms and develop effective antitoxin drugs[41]. - The company has developed antigen purification technology that maintains high antigenicity while ensuring the inactivation of toxins[42]. Market Expansion and Strategy - The company is expanding its market presence in Southeast Asia, targeting a 25% market share in the region by 2025[14]. - The company continues to expand its market presence, particularly in the sales of antivenom serum and tetanus immunoglobulin products, which saw year-on-year growth[22]. - The company has provided a forward guidance of 10% revenue growth for the second half of 2023, projecting total revenue to reach approximately 550 million CNY[14]. - New product development includes the launch of a novel immunoglobulin product, expected to contribute an additional 50 million CNY in revenue by the end of 2023[14]. - The company is actively pursuing technology upgrades and new product development to strengthen its core competitiveness and expand its market presence[63]. Risks and Challenges - The company has identified potential risks related to regulatory changes, which could impact future product approvals and market access[14]. - The company faces risks related to the concentration of suppliers for horses used in the production of its main products, which could impact production stability if suppliers fail to meet requirements[71]. - The company's main revenue sources are relatively concentrated in anti-snake venom serum and tetanus immunoglobulin, posing risks if sales or market prices decline significantly[72]. - The company’s products are included in the National Essential Medicines List, but future adjustments to this list could adversely affect operations[75]. - The company faces risks related to the uncertainty of drug development success and potential impairment of long-term equity investments[79]. Environmental and Compliance - The company has established pollution control facilities, including ammonium sulfate recovery and activated carbon purification systems, to ensure compliance with environmental regulations[102]. - The company has implemented automatic online monitoring for wastewater discharge to ensure compliance with environmental standards[102]. - The company has a comprehensive emergency response plan for environmental incidents, updated in 2023[103]. - The company has developed a 2023 environmental self-monitoring plan, establishing monitoring standards for air, water, noise, soil, and groundwater[104]. - The company has committed to strict compliance with national environmental monitoring technical standards and quality management regulations[104]. Shareholder and Governance - The company held a shareholders' meeting on May 15, 2023, where all proposals were approved without any rejections[93]. - The company did not propose any profit distribution or capital reserve transfer plans for the first half of the year[96]. - Major shareholders have pledged not to transfer or manage their shares during the lock-up period, with a commitment to maintain the share price above the IPO price for two years post-lock-up[112]. - The company has committed to a share lock-up period of 36 months for major shareholders following the IPO[110]. - The company emphasizes compliance with legal responsibilities regarding share transfers and lock-up commitments[120]. Fundraising and Financial Management - The company reported a total fundraising amount of ¥893,791,800, with a net amount of ¥784,923,575 after deducting issuance costs[173]. - As of the end of the reporting period, the cumulative investment of raised funds reached ¥143,285,582.91, representing an investment progress of 18.25%[173]. - The company approved the use of RMB 115 million of raised funds to permanently supplement working capital, accounting for 29.88% of the total raised funds[177]. - The company has approved the use of up to RMB 700 million of idle raised funds for cash management, with a usage period not exceeding 12 months[176]. - The company will strengthen fundraising management to mitigate risks associated with fund usage and ensure compliance with relevant regulations[133].

方正证券承销保荐有限责任公司 关于上海赛伦生物技术股份有限公司 部分募投项目延期的核查意见 方正证券承销保荐有限责任公司（以下简称"保荐机构"）作为上海赛伦生 物技术股份有限公司（以下简称"公司"或"赛伦生物"）首次公开发行股票并 在科创板上市及持续督导的保荐机构，根据《上海证券交易所科创板股票上市规 则（2020 年 12 月修订）》《上海证券交易所科创板上市公司自律监管指引第 1 号 —规范运作》《上市公司监管指引第 2 号—上市公司募集资金管理和使用的监管 要求》以及《科创板上市公司持续监管办法（试行）》等相关规定，对赛伦生物 部分募投项目延期的事项进行了审慎核查，情况如下： 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意上海赛伦生物技术股份有限公司首 次公开发行股票注册的批复》（证监许可[2022]204 号）的批准，公司获准向社会 公开发行人民币普通股 2,706 万股，每股面值为 1.00 元，每股发行价格为 33.03 元，公司收到募集资金总额为 89,379.18 万元，扣除发行费用 10,886.82 万元，募 集资金净额为 78,492.36 万元。上述募集资金已于 2022 ...

证券代码：688163 证券简称：赛伦生物 公告编号：2023-021 上海赛伦生物技术股份有限公司 关于部分募投项目延期的公告 本公司董事会及除董事长范志和先生外的全体董事保证本公告内容不存在 任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整 性依法承担法律责任。 上海赛伦生物技术股份有限公司（以下简称"公司"）于 2023 年 8 月 28 日 分别召开第三届董事会第十五次会议、第三届监事会第十一次会议，审议通过了 《关于部分募投项目延期的议案》，同意公司对募投项目"上海赛伦生物技术股 份有限公司厂房扩建项目"达到预定可使用状态的时间进行延期。独立董事对本 事项发表了明确同意的独立意见，保荐机构方正证券承销保荐有限责任公司（以 下简称"方正证券"或"保荐机构"）对本事项出具了明确的核查意见。上述议 案无需提交公司股东大会审议。现将相关情况公告如下： 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意上海赛伦生物技术股份有限公司首 次公开发行股票注册的批复》（证监许可【2022】204 号）的批准，公司获准向社 会公开发行人民币普通股 2,706 万股，每股面值为 1.00 元 ...